TrialJournal of immunology research2014

Fcγ-receptor IIIA polymorphism p.158F has no negative predictive impact on rituximab therapy with and without sequential chemotherapy in CD20-positive posttransplant lymphoproliferative disorder.

Heiner Zimmermann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.